

Formulary Update

November 2022

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since September 2022. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Morphine sulfate (Actimorph)	Available on advice of the palliative care team when administration of low doses with oral morphine liquid is deemed unsuitable.	4.7.2	New drug assessment
Treprostinil	Restricted to initiation and prescribing by specialists in the Scottish Pulmonary Vascular Unit or similar specialists for use in chronic thromboembolic pulmonary hypertension.	2.8.1	New drug assessment
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Dupilumab	Change to restriction: Restricted to specialist use for patients with severe asthma with type 2 inflammation and blood eosinophils ≥ 150 cells/microlitre and FeNO ≥ 25 parts per billion, and ≥ 4 exacerbations in the 12 months prior to initiating biologic treatment (anti-IgE or anti-IL-5 therapies) and who still experience ≥ 2 exacerbations per year despite this biologic treatment.	3.4.2	Formulary appeal